Environmental Contaminants Affects Unborn Baby.
A rich woman's revelation to environmental contaminants affects her unborn baby's heart rate and movement, a new learn says in June 2013. "Both fetal motor activity and heart rate show how the fetus is maturing and give us a way to evaluate how exposures may be affecting the developing nervous system," swat lead author Janet DiPietro, associate dean for research at the Johns Hopkins Bloomberg School of Public Health, said in a sect news release who is phil. The researchers analyzed blood samples from 50 high- and low-income fertile women in and around Baltimore and found that they all had detectable levels of organochlorines, including DDT, PCBs and other pesticides that have been banned in the United States for more than 30 years.
High-income women had a greater concentration of chemicals than low-income women tip brand club. The blood samples were nonchalant at 36 weeks of pregnancy, and measurements of fetal quintessence toll and movement also were taken at that time, according to the study, which was published online in the Journal of Exposure Science and Environmental Epidemiology 2013.
Showing posts with label effects. Show all posts
Showing posts with label effects. Show all posts
Wednesday, December 25, 2013
Saturday, November 23, 2013
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects
An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved therapeutical prostate cancer vaccine, Provenge, is safe-deposit and has few team effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy medworldplus. "Provenge was approved based on both security and clinical data," said edge researcher Dr Simon J Hall, seat of urology at Mount Sinai Medical Center in New York City.
This aegis data shows that there are very limited side effects, Hall added. The utility of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer airs effects than chemotherapy, which is the only other treatment option for these patients, Hall explained click. In addition, Provenge has improved survival over chemotherapy, he added.
The typical survival time for men given Provenge is 4,5 months, although some patients axiom their lives extended by two to three years. "This is a newly to hand treatment, with very limited side effects, compared to anything else that a man would be insomuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual assembly in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved importance of sprightliness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do discharge activities without any restrictions, the researchers noted.
The newly approved therapeutical prostate cancer vaccine, Provenge, is safe-deposit and has few team effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy medworldplus. "Provenge was approved based on both security and clinical data," said edge researcher Dr Simon J Hall, seat of urology at Mount Sinai Medical Center in New York City.
This aegis data shows that there are very limited side effects, Hall added. The utility of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer airs effects than chemotherapy, which is the only other treatment option for these patients, Hall explained click. In addition, Provenge has improved survival over chemotherapy, he added.
The typical survival time for men given Provenge is 4,5 months, although some patients axiom their lives extended by two to three years. "This is a newly to hand treatment, with very limited side effects, compared to anything else that a man would be insomuch as in this state," Hall said. Hall was to present the results on Monday at the American Urological Association annual assembly in San Francisco.
Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved importance of sprightliness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do discharge activities without any restrictions, the researchers noted.
Subscribe to:
Posts (Atom)